Tsuruo T, Sugimoto Y, Hamada H, Roninson I, Okumura M, Adachi K, Morishima Y, Ohno R
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo.
Jpn J Cancer Res. 1987 Dec;78(12):1415-9.
We have examined the expression of P-glycoprotein in clinical leukemic cell samples by using a monoclonal antibody (MRK16) against P-glycoprotein. We found that leukemia cells isolated from 3 out of 6 patients with blast crisis of chronic myelogenous leukemia were reactive to MRK16. These 3 cell lines expressed high levels of mdr1 mRNA, which codes for P-glycoprotein. The present result indicates that the clinically refractory state of the tumor may be predicted in part by determining P-glycoprotein expression using the monoclonal antibody against P-glycoprotein, and the mdr1 probe.
我们使用抗P-糖蛋白的单克隆抗体（MRK16）检测了临床白血病细胞样本中P-糖蛋白的表达。我们发现，从6例慢性髓性白血病急变期患者中的3例分离出的白血病细胞对MRK16有反应。这3种细胞系表达高水平的mdr1 mRNA，其编码P-糖蛋白。目前的结果表明，通过使用抗P-糖蛋白的单克隆抗体和mdr1探针检测P-糖蛋白表达，可部分预测肿瘤的临床难治状态。
